Provided By GlobeNewswire
Last update: Feb 26, 2025
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –
– Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures –
Read more at globenewswire.comNASDAQ:ASMB (6/2/2025, 4:04:09 PM)
15.4
+1.25 (+8.83%)
Find more stocks in the Stock Screener